Endeavor Biomedicines vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Endeavor Biomedicines is a Cambridge-based clinical-stage biotech targeting drivers of fibrosis and oncology with precision small molecules; raised $450M in a 2024 Series B led by Arch Venture Partners and GV;
About
Endeavor Biomedicines is a clinical-stage biotechnology company founded in 2022 and headquartered in Cambridge, Massachusetts, that is developing precision small-molecule medicines targeting the molecular drivers of fibrotic diseases and cancer. The company's scientific focus is on identifying and inhibiting protein targets that are specifically activated in disease states — particularly in idiopathic pulmonary fibrosis (IPF), a fatal scarring lung disease, and solid tumor oncology. Endeavor's platform emphasizes structural biology and medicinal chemistry to design compounds with high selectivity for disease-driving targets, minimizing off-target effects that have limited the tolerability of earlier investigational drugs. The company is led by CEO Tomas Kiselak and supported by a scientific advisory board of leading experts in fibrosis and cancer biology.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.